profile during sleeping hours application_number US 82748510 A description the inventive method of treatment is designed in part to address problems associated with the day time administration of pramipexole such as interrupted sleep patterns resultant fatigue need for more u201c therapy u201d and the need for better motor functionality during waking hours the inventive method which comprises dosing pramipexole formulation late in the day allows for rising ascending pk profiles through sleeping hours and into the following afternoon this new dosing paradigm offers higher and ascending drug exposure during early morning hours to enable and improve motor functionality at time of waking and through early part of the day additionally the new dosing paradigm and associated higher ascending plasma levels may enable more continuous sleep due to blunted cmax vs pramipexole ir in the case of pd or rls thus translating into less daytime fatigue as has been reported by mirapex u00ae users controlled release formulations suitable for the inventive method are preferably designed in such a way that pramipexole is released from the formulation along a pre determined release profile exemplary formulations are discussed hereinbelow and may also be found in u s patent application ser no 12 478 979 filed jun 5 2009 the disclosure of which is incorporated herein in its entirety by reference in.